Travere Therapeutics, Inc.

NasdaqGM:TVTX Stock Report

Market Cap: US$1.7b

Travere Therapeutics Past Earnings Performance

Past criteria checks 0/6

Travere Therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 5.5% per year.

Key information

-25.6%

Earnings growth rate

-14.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-5.5%
Return on equityn/a
Net Margin-171.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Oct 31
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Oct 07
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 30

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Sep 10
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22
Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08
New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05
It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 16
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Oct 13

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Oct 06
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Sep 29

Travere, CSL kidney disease drug sparsentan gets review in EU

Aug 22

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How Travere Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:TVTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24203-3492580
30 Jun 24178-3832600
31 Mar 24156-41626465
31 Dec 23145-3762660
30 Sep 23130-3732590
30 Jun 23120-3682440
31 Mar 2392-3522170
31 Dec 22109-3311980
30 Sep 22137-2971830
30 Jun 22178-2491660
31 Mar 22229-2021600
31 Dec 21132-2171260
30 Sep 21221-250144-93
30 Jun 21204-237139-61
31 Mar 21198-224139-30
31 Dec 20198-1691360
30 Sep 20194-78128130
30 Jun 20187-92125131
31 Mar 20184-105129138
31 Dec 19175-1461290
30 Sep 19172-124127137
30 Jun 19169-142124136
31 Mar 19165-125110133
31 Dec 18164-103104124
30 Sep 18163-113104111
30 Jun 18162-7610197
31 Mar 18160-6710582
31 Dec 17155-6010178
30 Sep 17150-5110179
30 Jun 17144-7010279
31 Mar 17138-709677
31 Dec 16134-489271
30 Sep 16127-428866
30 Jun 161211018762
31 Mar 16112898455
31 Dec 151001178050
30 Sep 1584916950
30 Jun 1564-336448
31 Mar 154645351
31 Dec 1428-1115948
30 Sep 1414-954938
30 Jun 146-893627
31 Mar 140-1053114

Quality Earnings: TVTX is currently unprofitable.

Growing Profit Margin: TVTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TVTX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare TVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TVTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies